Alex Michelson
Psychiatry · Mission Viejo, CANPI 1255372389
Payments from drug & device makers
Across 177 payments — averaging $25.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$955
- Supernus Pharmaceuticals, Inc.$705
- Johnson & Johnson$686
- Bausch Health US, LLC$551
- Ironshore Pharmaceuticals Inc.$296
- Takeda Pharmaceuticals U.S.A., Inc.$201
- plus $1K from 14 others
What the payments were for
- Consulting fees$2004%
- Food & beverage$4,33895%
- Education$281%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 37 | $955 |
| Supernus Pharmaceuticals, Inc. | 26 | $705 |
| Johnson & Johnson | 22 | $686 |
| Bausch Health US, LLC | 24 | $551 |
| Ironshore Pharmaceuticals Inc. | 11 | $296 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $201 |
| Janssen Scientific Affairs, LLC | 1 | $200 |
| Adlon Therapeutics L.p. | 10 | $195 |
| Otsuka America Pharmaceutical, Inc. | 8 | $169 |
| Corium, LLC | 6 | $130 |
| Tris Pharma Inc | 5 | $113 |
| Almatica Pharma LLC | 3 | $96 |
| Noven Therapeutics, LLC | 4 | $81 |
| Eisai Inc. | 3 | $50 |
| Vanda Pharmaceuticals Inc. | 2 | $38 |
| Neurocrine Biosciences, Inc. | 1 | $26 |
| Tempus AI, Inc | 1 | $22 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,566 in reported general payments places this provider in the 85th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 20 | $4,153 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 13 | $522 |
| Trazodone Hcl | 52 | $478 |
| Clonazepam | 67 | $468 |
| Lamotrigine | 28 | $466 |
| Gabapentin | 18 | $431 |
| Escitalopram Oxalate | 35 | $414 |
| Lorazepam | 26 | $265 |
| Fluoxetine Hcl | 26 | $148 |
| Bupropion Hcl SrBupropion Hcl | 16 | $143 |
| Zolpidem Tartrate | 11 | $133 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 11 | $123 |
| Buprenorphine Hcl | 11 | $111 |
| Bupropion XlBupropion Hcl | 12 | $94 |
| Lithium Carbonate | 13 | $76 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Mission Viejo
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
- Donald AndersonBanning$10.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.